OBJECTIVE To systematically sort out the drugs causing drug-induced liver injury （DILI） and their relevant information， and to develop the Expert consensus on the medication catalog for drug-induced liver injury and rational drug use （hereinafter referred to as the Consensus）， so as to provide a reference for rational clinical use. METHODS Systematic searches were conducted across various literature databases， guideline retrieval websites and professional liver injury websites. Drugs identified as causing DILI from the included literature and online resources were extracted and assigned scores based on source credibility： three points for LiverTox A-class drugs and two points for B-class drugs； two points for drugs from Hepatox and guidelines； and one point for drugs from consensus and related literature sources. Drugs classified as LiverTox category A/B or with total scores ≥4 were included in the preliminary list of DILI-causing drugs. Opinions were collected and integrated from a multidisciplinary expert panel comprising 45 medical and pharmaceutical experts from 27 provinces across China through three rounds of the Delphi method （including questionnaires and discussion sessions）， and after revision， the final version of Consensus was formed. RESULTS & CONCLUSIONS This Consensus included 12 traditional Chinese medicines （TCMs） such as Polygoni Multiflori Radix and Ephedrae Herba， 151 Western medicines including amiodarone and atorvastatin， along with rational use information. For TCM， eight rational use information were included： evidence-based score， liver injury classification based on pathogenesis， liver injury classification based on biochemical abnormality pattern， clinical phenotype， laboratory examination manifestations， latency period， recovery time， and management strategies. For Western medicines， six additional items were included based on the TCM， namely liver function monitoring， discontinuation， contraindications， cautions， dose adjustments， and risk factors， totaling 14 items. This Consensus systematically compiles DILI drugs and their rational use information， which will support clinicians in enhancing the prevention， identification， and management of DILI， reducing the incidence of liver injury， and ensuring patient medication safety and efficacy.

Ultrasound-guided percutaneous lung needle biopsy (US-PLNB) is a pivotal diagnostic technique for subpleural pulmonary lesions, offering significant advantages such as real-time imaging, absence of ionizing radiation, and high operational flexibility. To standardize its clinical application and enhance both procedural safety and diagnostic accuracy, a multidisciplinary panel of experts was convened by eleven authoritative Chinese academic societies, including Chinese Society of Ultrasound in Medicine. Based on the latest domestic and international evidence-based medicine, this panel developed Chinese expert consensus on ultrasound-guided percutaneous lung needle biopsy (2025 edition). This consensus systematically elaborates on the indications and contraindications, preprocedural assessment and preparation, intraoperative techniques, complication prevention and management, and post-procedural care for US-PLNB. Furthermore, it puts forward 18 specific evidence-based recommendations. The primary aim of this consensus is to provide radiologists and clinicians with standardized operational guidance, promote the standardized application of US-PLNB, and ultimately improve patient care for individuals with pulmonary diseases.

The liver is the primary target organ for hematogenous metastasis of colorectal cancer, and colorectal cancer liver metastasis is one of the key and challenging aspects in its treatment. In order to improve the diagnosis and comprehensive treatment of colorectal cancer liver metastasis in China, the guideline development group has summarized advanced experiences and the latest achievements from both domestic and international sources, and has once again revised and updated the Guideline for the diagnosis and comprehensive treatment of colorectal cancer liver metastases (2025 edition) to continuously provide guidance and reference for clinical practice in this field in China.

Objective To provide scientific and normative guidance for capacity building and quality control standards for vision health management service institutions, thereby promoting the standardization and professional development of the industry, enhancing service quality, and improving the effectiveness of myopia prevention and control. Methods A multidisciplinary expert panel organized by Society of Vision Health Management, Chinese Health Association, based on standards such as the ^"Technical Specifications for Vision Health Management Services for Primary and Secondary School Students^" (T/CHAA 008-2019) and combined with field research data, revised and formed this consensus through multiple rounds of meetings and discussions. Results This consensus clarifies the positioning of service institutions, core service capability requirements (covering basic configuration, personnel and equipment, service processes, scope, and competency levels), and quality control points throughout the service process. It establishes an evaluation framework centered on ^"foundational support - service implementation - management effectiveness - outcome output.^" Conclusion This consensus provides systematic guidance for the standardized construction, capacity evaluation, and quality control of vision health management service institutions, which is of great significance for safeguarding the vision health of children and adolescents.

OBJECTIVE To provide guidance on the scientific and standardized application of artificial intelligence （AI） and multimodal fusion techniques in constructing predictive models for adverse drug reactions （ADR） of antineoplastics， thereby enhancing the safety of antineoplastic therapy. METHODS Jointly initiated by the Clinical Pharmacy and Translational Pharmacy Society of the Liaoning Provincial Life Sciences Association and other professional societies， and organized by the Fourth Affiliated Hospital of China Medical University， the writing group conducted a comprehensive search of domestic and international databases using keywords such as “multimodal data” “artificial intelligence” “adverse drug reactions”“antineoplastics” and “models” to collect guidelines， expert consensuses， and relevant guidance literature. Based on this search， and combined with China’s practical experience in applying AI to oncology pharmaceutical care， a consensus framework and preliminary recommendations were drafted. Following evaluation and discussion by an external expert panel， the writing group incorporated the assessment results and formulated recommendations based on those endorsed by 90% or more of the experts. RESULTS &CONCLUSIONS After multiple rounds of review， discussion and revision， this consensus outlines the process for constructing an ADR prediction model of antineoplastics， encompassing “defining research objectives-data preparation-selection of algorithmic frameworks-design of multimodal data fusion strategies-model training and validation-interpretability analysis-clinical deployment-publication of results”. It also formulates 18 recommendations regarding core aspects such as data preparation， algorithm framwork selection， multimodal data fusion strategy design， model validation and interpretability analysis， and clinical deployment. These recommendations are intended for use by physicians in the field of oncology， clinical pharmacists， researchers， and AI technology developers to assist in making optimal clinical treatment decisions.

Objective: Polycystic ovary syndrome (PCOS) is a gynecological, endocrine condition characterized by ovulatory disorders, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. PCOS has significant metabolic and reproductive implications that affect the quality of life of women. This PCOS guideline summary is based on the Indonesian Reproductive Endocrinology and Fertility Association guidelines for PCOS. This guideline is expected to guide the diagnosis and long-term management of PCOS. Methods: We searched scientific evidence on the Cochrane and PubMed databases using the keyword “polycystic ovary syndrome”. This evidence was reviewed by experts in the field of obstetrics and gynecology, and recommendations were made based on scientific evidence while considering patient values, costs, and resources. Results: A total of 127 recommendations and practice points were made regarding the diagnosis and management of PCOS. The levels of available health services and management algorithms for PCOS in Indonesia are also included. Conclusion The first-line treatment for managing hyperandrogenism and menstrual disorders in patients with PCOS is combined oral contraceptives. The first-line treatment for ovulation induction is letrozole, while clomiphene citrate, metformin, gonadotropins, and ovarian surgery serve as the second-line treatment. The third-line treatments included in vitro fertilization, with or without in vitro maturation.

In the past 6 years, significant breakthroughs have been achieved in the treatment of heart failure (HF), especially in drug therapy. The classification of chronic HF and the treatment methods for HF and its complications are also constantly being updated. In order to apply these results to the diagnosis and treatment of patients with HF in China and further improve the level of diagnosis and treatment of HF in China, the HF Group of Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, Chinese HF Association of Chinese Medical Doctor Association, and Editorial Board of Chinese Journal of Cardiology have organized an expert group and update the consensus and evidence-based treatment methods in the field of HF based on the latest clinical research findings at home and abroad, combined with the national conditions and clinical practice in China, and referring to the latest foreign HF guidelines while maintaining the basic framework of the 2018 Chinese Guidelines for Diagnosis and Treatment of HF.

OBJECTIVE To standardize the implementation methods for therapeutic drug monitoring （TDM） of meropenem and ensure the accuracy of TDM results， thereby facilitating the scientific development of individualized treatment regimens for meropenem. METHODS The expert consensus was launched by the Society of Therapeutic Drug Monitoring Pharmacists of Chinese Pharmacists Association. The compilation team comprised experts in clinical pharmacy， TDM technology， and pharmaceutical administration， and it was developed in accordance with the relevant recommendations from the methodology handbook of WHO and the guidelines for TDM guidelines development. Twelve clinical questions were selected through a three- round Delphi voting process conducted by the committee， followed by a comprehensive review of relevant original articles， systematic reviews， and guidelines through general databases. The GRADE approach was employed to evaluate the quality of evidence so as to formulate the consensus recommendations. The experts’ opinions were organized， revised and finally formed into a consensus. RESULTS Ultimately， the consensus presented 14 recommendations， mainly regarding all aspects of TDM processes including necessity， method， monitor timing， target PK/PD， medication adjustments based on PK/PD， and the quality control of TDM. CONCLUSIONS This consensus provides standardized methods and process suggestions for meropenem TDM in medical institutions in China， and is of great significance for meropenem individualized drug use， improving clinical efficacy， and ensuring drug safety.

war ; Armed Conflicts ; Nuclear Energy ; Atomic Energy ; Radiation ; Nuclear Weapons